Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.86 -0.13 (-0.27%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive. ↗

October 17, 2025

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.

Via Investor's Business Daily

Topics Government

Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic ↗

October 17, 2025

Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.

Via Stocktwits

Topics Government

Eli Lilly Shares Are Trading Lower Friday: What's Going On? ↗

October 17, 2025

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.

Via Benzinga

Topics Government

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? ↗

October 17, 2025

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.

Via Benzinga

Topics Government

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder ↗

October 15, 2025

Via Stocktwits

Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments

October 17, 2025

The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently,...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Regional Banks’ Credit Concerns Drag Dow Futures: NVO, WAL, ZION, IBKR Among Stocks To Watch ↗

October 17, 2025

While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%.

Via Stocktwits

Topics ETFs Earnings Fraud

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗

October 17, 2025

These stocks have climbed in the triple digits over the past few years.

Via The Motley Fool

Eli Lilly, Novo Nordisk Stocks Fall After-Hours As Trump Pledges Swift Price Cuts For ‘Fat-Loss Drugs’ ↗

October 16, 2025

Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks.

Via Stocktwits

Topics Economy Government

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' ↗

October 16, 2025

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.

Via Benzinga

Topics Government

What's Driving the Market Sentiment Around Novo Nordisk AS? ↗

October 16, 2025

Via Benzinga

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem ↗

October 16, 2025

Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare.

Via Benzinga

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? ↗

October 16, 2025

Find out if the deal Omeros announced is enough of a reason to buy this stock.

Via The Motley Fool

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside ↗

October 15, 2025

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Via Stocktwits

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗

October 15, 2025

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Via MarketBeat

Topics World Trade

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal ↗

October 15, 2025

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties.

Via Benzinga

Meet the 1.4% Yield Dividend Stock That Could Soar in 2026 ↗

October 15, 2025

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.

Via The Motley Fool

Why Is Scholar Rock Stock Trading Lower On Monday? ↗

October 13, 2025

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Via Benzinga

Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗

October 13, 2025

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

Via Stocktwits

Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗

October 13, 2025

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

Via The Motley Fool

The Smartest Growth Stock to Buy With $100 Right Now ↗

October 13, 2025

This beaten-down drugmaker is well positioned to turn things around.

Via The Motley Fool

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Topics ETFs Government World Trade

3 Top Healthcare Stocks to Buy in October ↗

October 13, 2025

Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders.

Via The Motley Fool

Topics Economy Government Intellectual Property

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth ↗

October 13, 2025

Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability.

Via Chartmill

Should You Buy Novo Nordisk Right Now? ↗

October 12, 2025

The fallen pharma giant could make a big comeback in 2026.

Via The Motley Fool

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations ↗

October 10, 2025

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

Via Benzinga

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions

October 09, 2025

Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in...

Via MarketMinute

Eastover Opens a Brand New $3.3 Million Novo Nordisk Position ↗

October 09, 2025

Via The Motley Fool

Topics Regulatory Compliance

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion ↗

October 09, 2025

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.